We only have this paper's title and publication details.
Read it at the sourceCaptured external expert commentary on this paper, strongest first. Original sources are linked where available.
“I'm absolutely confident that the evidentiary standard for FDA authorization of generative AI tools will change.”
“Patients and clinicians deserve a regulatory approach that keeps pace with the rapid innovation of digital health technologies. By inviting input from the public, we are launching a transparent process to inform the development of an approach that safeguards patients and consumers, advances innovation, and serves as a potential model for regulators around the world.”
“Generative AI–enabled medical devices are poised to reshape the health technology landscape, and the FDA has an important responsibility to provide thoughtful leadership for this new era. This discussion paper advances the frontiers of regulatory science and propels a critical conversation about how to enable beneficial innovation, protect public health, and preserve trust.”
No takes yet. Share an insight, caveat, or question.
Harlan M. Krumholz (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: